Last updated: September 3, 2026
Pralsetinib, marketed as Gavreto, is a selective RET tyrosine kinase inhibitor developed by Blueprint Medicines and commercialized with Roche. Its commercial opportunity is concentrated in biomarker-defined cancers: RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The drug has strong clinical differentiation against older multikinase inhibitors, but its addressable market is limited by RET prevalence, molecular-testing rates, competition from selpercatinib, and Roche’s withdrawal from the collaboration.
Blueprint regained U.S. rights after Roche exited the relationship. Gavreto is now a strategically secondary asset relative to Blueprint’s Ayvakit franchise. Its future value depends on continued access to RET-positive patients, payer coverage, commercial execution, and the timing of generic or competing RET-inhibitor entry.
What is pralsetinib and which cancers does it treat?
Pralsetinib is an oral, selective inhibitor of the RET kinase. RET is a driver oncogene in several cancers, including:
- RET fusion-positive NSCLC
- RET-mutant medullary thyroid cancer
- RET fusion-positive thyroid cancer
The FDA granted accelerated approval for Gavreto in 2020 based primarily on response rates and durability in the ARROW clinical trial. The initial approvals covered adults with metastatic RET fusion-positive NSCLC and patients with advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy. The FDA also approved the drug for advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and radioactive iodine-refractory disease where radioactive iodine was appropriate.[1]
Pralsetinib competes primarily with selpercatinib, marketed as Retevmo by Eli Lilly. Both drugs were designed specifically for RET-driven tumors and entered the market within months of each other.
How does pralsetinib work?
Pralsetinib blocks RET signaling caused by activating RET mutations and gene fusions. Its selectivity is intended to reduce the off-target toxicities associated with older multikinase inhibitors such as cabozantinib and vandetanib.
The commercial value of the mechanism depends on identifying RET alterations before treatment. Broad next-generation sequencing, liquid biopsy, and tissue-based testing are therefore central to the drug’s market penetration.
How large is the pralsetinib market?
The commercial market is meaningful but narrow. RET alterations occur in a small percentage of patients with common cancers.
| Indication |
Approximate RET-positive prevalence |
Commercial implication |
| NSCLC |
About 1% to 2% of cases |
Largest potential patient pool because lung cancer incidence is high |
| Medullary thyroid cancer |
Germline or somatic RET alterations in a substantial share of cases |
Smaller population but high biomarker concentration |
| Other thyroid cancers |
RET fusions occur in a minority of papillary and related thyroid tumors |
Supplemental opportunity |
| All solid tumors |
Low overall prevalence |
Supports tumor-agnostic development only if evidence expands |
The NSCLC opportunity is the largest by patient count. The thyroid-cancer opportunity has a higher concentration of RET alterations and can support durable treatment use, but the total number of eligible patients is smaller.
Market expansion depends on three factors:
- Routine molecular profiling at diagnosis and progression.
- Earlier use of selective RET inhibitors rather than chemotherapy or multikinase therapy.
- Broader reimbursement for comprehensive genomic testing.
In practice, the eligible population is smaller than the theoretical RET-positive population because testing is incomplete, some patients are medically unsuitable for oral targeted therapy, and some receive competing drugs.
How does pralsetinib compare with selpercatinib?
Selpercatinib is the principal commercial competitor. Both drugs have approvals across RET-driven lung and thyroid cancers and both are used in treatment settings where high response rates and intracranial activity matter.
| Commercial factor |
Pralsetinib |
Selpercatinib |
| Brand |
Gavreto |
Retevmo |
| Developer |
Blueprint Medicines |
Eli Lilly, originally developed by Loxo Oncology |
| Core target |
RET |
RET |
| Initial U.S. approval |
2020 |
2020 |
| Key markets |
RET fusion-positive NSCLC; RET-mutant and RET fusion-positive thyroid cancer |
Similar RET-driven indications |
| Principal advantage |
Strong selective RET profile and clinical activity in treatment-naive disease |
Broad clinical development, established commercial infrastructure, and significant Lilly resources |
| Principal risk |
Smaller commercial platform and Roche collaboration disruption |
Competitive pressure from another selective RET inhibitor |
| Market access issue |
Narrow biomarker-defined population |
Same |
Head-to-head superiority has not been established. Treatment choice is influenced by physician familiarity, central nervous system activity, adverse-event management, drug interactions, formulary status, patient comorbidities, and manufacturer support.
Selpercatinib has a commercial advantage from Lilly’s scale and the integration of Loxo’s oncology development capabilities. Pralsetinib has a disadvantage because Blueprint’s commercial infrastructure is built primarily around Ayvakit and other pipeline programs rather than a broad oncology portfolio.
What were the FDA milestones for Gavreto?
| Date |
FDA milestone |
| Sept. 4, 2020 |
Accelerated approval for metastatic RET fusion-positive NSCLC |
| Sept. 4, 2020 |
Accelerated approvals covering RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer in specified patients |
| 2021 onward |
Continued postmarketing and confirmatory development under the accelerated-approval framework |
| 2023-2024 |
U.S. commercial rights transitioned back from Roche to Blueprint |
The accelerated-approval framework creates regulatory obligations. The sponsor must verify clinical benefit through confirmatory evidence. Failure to satisfy those obligations can create risks ranging from label restrictions to withdrawal of an indication.
Gavreto’s regulatory profile differs from that of a broadly indicated oncology product. Its label depends on molecular selection, and regulatory value is tied to the continued recognition of RET alterations as actionable biomarkers.
What is the Orange Book status of pralsetinib?
Gavreto is a small-molecule prescription drug, so its principal U.S. competition risk is generic substitution rather than biosimilar competition. The FDA Orange Book is the central source for listed patents, pediatric exclusivity, and associated expiration dates.
The relevant IP categories include:
- Composition-of-matter protection for pralsetinib and related chemical compounds.
- Pharmaceutical-composition and salt-form patents.
- Treatment patents covering RET-driven cancers.
- Dosing and administration claims.
- Combination or patient-selection claims.
- Manufacturing and crystalline-form protection.
Patent protection is likely to extend beyond the basic five-year new chemical entity period, but the economic value of later-expiring patents depends on claim scope and enforceability. Formulation and method-of-use patents are generally more vulnerable than a well-supported composition patent because generic applicants may attempt design-around strategies.
A complete Orange Book assessment must distinguish between:
- Patents listed against the reference product.
- Patents covering the active ingredient.
- Patents covering only a specific indication or regimen.
- Regulatory exclusivity that expires separately from patent rights.
- Pediatric exclusivity, if granted.
No biosimilar pathway applies to pralsetinib. An ANDA applicant could challenge listed patents through Paragraph IV certification once eligible patent protections and regulatory exclusivities permit filing.
When could generic pralsetinib enter the U.S. market?
Generic entry depends on the earliest enforceable patent expiry, the outcome of any Paragraph IV litigation, settlement terms, and whether the generic applicant seeks approval for all or only unprotected indications.
The commercial entry scenarios are:
Early entry through Paragraph IV litigation
A generic applicant could file an ANDA with a Paragraph IV certification alleging that relevant patents are invalid, unenforceable, or not infringed. A timely patent lawsuit can trigger a 30-month stay of FDA approval under the Hatch-Waxman Act, subject to statutory exceptions.[2]
At-risk launch
A generic manufacturer could launch before final resolution if it believes the patent risk is manageable. This could expose the manufacturer to damages and injunction risk, while creating immediate price pressure for Blueprint.
Launch after patent expiry
This is the lowest-risk scenario for the generic manufacturer. A later entry date would preserve branded pricing for longer but would still threaten rapid erosion because oral oncology products can convert quickly after generic approval.
Skinny-label entry
If method-of-use patents remain listed for only some indications, a generic company may seek approval for unpatented uses. The practical impact depends on prescribing behavior, pharmacy substitution, payer controls, and the ability to enforce indication-specific restrictions.
The economic risk is greater if the key composition patent expires before the principal method-of-use patents. A composition patent generally gives the strongest barrier because generic substitution would implicate the active ingredient itself.
What patent protections are most important for pralsetinib?
The strongest protection would come from claims that cover pralsetinib itself or a broad, commercially necessary chemical form. Later patents can extend nominal protection but may not prevent all competition.
| Patent category |
Typical strength |
Commercial relevance |
| Composition of matter |
Highest |
Can block products containing the active molecule |
| Salt or crystalline form |
Moderate to high |
May restrict specific manufacturing or product forms |
| Formulation |
Moderate |
Can be designed around depending on claim language |
| Method of use |
Moderate |
May support indication-specific enforcement |
| Dosing regimen |
Variable |
Vulnerable if alternative dosing is clinically acceptable |
| Manufacturing process |
Variable |
Strong only if the process is necessary or difficult to replicate |
Geographic coverage is most commercially important in the United States, European Union, Japan, and China. China is strategically important because Zai Lab has been associated with commercial activity for Gavreto in Greater China. Patent term, regulatory exclusivity, local manufacturing, and pricing rules differ materially by jurisdiction.
Which companies are challenging pralsetinib commercially?
The principal competitive threats are:
- Eli Lilly through Retevmo, the direct selective RET inhibitor competitor.
- Generic manufacturers after the relevant U.S. patent and exclusivity barriers expire.
- Cabozantinib and vandetanib in settings where physicians use older multikinase inhibitors.
- Clinical-trial competitors developing next-generation RET inhibitors for resistance mutations and central nervous system disease.
The most important near-term competitive dynamic is not generic entry. It is the contest between Gavreto and Retevmo for newly diagnosed RET-positive patients, treatment sequencing, and patients who progress after first-line RET inhibition.
Next-generation RET inhibitors could pressure both products if they demonstrate improved activity against solvent-front mutations, better brain penetration, lower discontinuation rates, or activity after prior selective RET therapy.
What happened to Roche’s commercial relationship with Blueprint?
Blueprint entered into a global collaboration with Roche covering pralsetinib development and commercialization. Roche provided global commercial scale, regulatory resources, and access to established oncology channels. The arrangement reduced Blueprint’s direct commercial burden but also limited Blueprint’s control over the product’s market strategy.
Roche later discontinued the collaboration and returned rights to Blueprint. Blueprint’s recovery of U.S. rights gives the company direct control over pricing, promotion, and lifecycle management. It also transfers commercial costs and execution risk back to Blueprint.
The change has four financial consequences:
- Blueprint can capture a larger share of future product economics.
- Blueprint must fund commercial activities that Roche previously supported.
- Gavreto becomes more dependent on Blueprint’s smaller sales infrastructure.
- The company can align Gavreto with its broader precision-oncology portfolio.
The transaction removed a large pharmaceutical partner from the product but did not remove the underlying competitive pressure from Retevmo.
What has been the financial trajectory of pralsetinib?
Gavreto has not developed into a major revenue product on the scale of a broad oncology blockbuster. Its revenue ceiling is constrained by a small patient population and direct competition from selpercatinib.
Roche’s public reporting showed relatively modest sales for Gavreto compared with its largest oncology products. Blueprint’s financial profile is dominated by Ayvakit, particularly in gastrointestinal stromal tumor and systemic mastocytosis, rather than Gavreto.[3][4]
| Financial driver |
Effect on pralsetinib |
| RET-positive patient prevalence |
Limits total volume |
| Testing penetration |
Determines how many eligible patients are identified |
| U.S. price and duration |
Supports revenue per treated patient |
| Competition from Retevmo |
Limits share and weakens pricing leverage |
| Roche exit |
Reduces partner support but increases Blueprint’s control |
| Generic timing |
Creates the largest long-term price risk |
| CNS efficacy and resistance activity |
Can improve treatment preference and duration |
| Payer policies |
Affect initiation and continuation rates |
The product’s economics are therefore better characterized as a specialized oncology franchise than as a high-growth platform asset. Incremental growth would need to come from market-share gains, increased testing, geographic expansion, additional RET-positive indications, or improved treatment sequencing.
How strong is the commercial outlook for pralsetinib?
The outlook is mixed.
Positive factors
- RET is a validated oncogenic driver.
- Selective RET inhibition is clinically superior to nonspecific kinase inhibition for appropriately selected patients.
- Molecular testing is becoming more routine in NSCLC and thyroid cancer.
- Oral targeted therapy supports outpatient use and repeat treatment.
- Blueprint now controls U.S. commercialization and lifecycle decisions.
Negative factors
- The eligible population is small.
- Retevmo has a powerful commercial owner in Eli Lilly.
- Roche’s withdrawal weakened the product’s prior commercial structure.
- Accelerated-approval obligations create regulatory execution risk.
- Generic entry could rapidly reduce net pricing after core patents expire.
- A next-generation RET inhibitor could disrupt treatment sequencing.
Gavreto has strategic value to Blueprint as part of a precision-oncology portfolio, but it is unlikely to be the company’s main financial engine unless the company materially expands the treated population or captures share from Retevmo.
What generic launch risks exist for pralsetinib?
The highest-risk launch scenario is a first generic entrant after loss of core composition protection. Oral oncology drugs often experience sharp price declines once generic substitution becomes available, although the impact can be moderated by limited patient volume, specialty-pharmacy distribution, reimbursement controls, and indication-specific prescribing.
Key indicators to monitor include:
- New Orange Book patent listings.
- ANDA filings and Paragraph IV litigation.
- Patent-term-extension decisions.
- FDA action on accelerated-approval obligations.
- Blueprint’s U.S. net product revenue.
- Retevmo market-share changes.
- New RET inhibitors in clinical development.
- Patent settlements that establish an authorized or licensed generic entry date.
How does pralsetinib compare with other RET therapies?
| Drug |
Company |
RET use |
Commercial position |
| Gavreto, pralsetinib |
Blueprint Medicines |
RET fusion and RET mutation-driven cancers |
Specialized product with direct U.S. control restored to Blueprint |
| Retevmo, selpercatinib |
Eli Lilly |
RET fusion and RET mutation-driven cancers |
Principal branded competitor with larger commercial infrastructure |
| Caprelsa, vandetanib |
Sanofi |
Medullary thyroid cancer |
Older, less selective therapy |
| Cometriq, cabozantinib |
Exelixis |
Medullary thyroid cancer |
Older multikinase option with broader off-target activity |
Pralsetinib’s competitive position depends less on broad market size than on physician preference within RET-positive treatment pathways. Brain metastases, tolerability, prior therapy, mutation status, and access are likely to determine product selection.
Key Takeaways
- Pralsetinib is a selective RET inhibitor marketed as Gavreto.
- Its main indications are RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer.
- The market is biomarker-defined and relatively small.
- Selpercatinib, marketed as Retevmo by Eli Lilly, is the primary branded competitor.
- Roche’s exit returned U.S. rights and commercial responsibility to Blueprint Medicines.
- Blueprint’s financial performance is driven primarily by Ayvakit, not Gavreto.
- Patent value depends on composition, formulation, method-of-use, and manufacturing claims, with the composition patent generally carrying the greatest weight.
- Generic risk will depend on Orange Book listings, Paragraph IV challenges, litigation outcomes, and any settlement entry date.
- Biosimilar competition is not relevant because pralsetinib is a small molecule.
- Long-term growth requires higher RET testing rates, additional indications, stronger share against Retevmo, or successful use in treatment sequencing.
FAQs About Pralsetinib Market Economics
Is pralsetinib a blockbuster drug?
No. Gavreto has a specialized commercial opportunity and has not reached the revenue scale associated with broad oncology blockbusters. The limited RET-positive population and competition from Retevmo constrain its ceiling.
Who owns the U.S. commercial rights to Gavreto?
Blueprint Medicines regained U.S. commercial rights after Roche exited the collaboration. Blueprint is responsible for U.S. commercialization and lifecycle strategy.
Does pralsetinib have biosimilar competition?
No. Pralsetinib is an orally administered small molecule. Future competition would generally come from generic versions approved through the ANDA pathway.
What is the biggest commercial threat to Gavreto?
The largest current threat is Retevmo, not generic entry. Eli Lilly’s commercial infrastructure and continued RET development give selpercatinib a strong competitive position.
Can increased genomic testing expand pralsetinib sales?
Yes. Higher use of tissue and liquid-biopsy testing can identify more RET-positive patients. The financial effect depends on whether those patients receive Gavreto rather than Retevmo or another RET-directed therapy.
References
-
U.S. Food and Drug Administration. (2020). FDA grants accelerated approval to pralsetinib for metastatic RET fusion-positive NSCLC. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Blueprint Medicines Corporation. (2024). 2023 annual report on Form 10-K. U.S. Securities and Exchange Commission.
-
Roche Holding AG. (2024). Annual report 2023. Roche.
-
Eli Lilly and Company. (2024). 2023 annual report. U.S. Securities and Exchange Commission.
